cognitive cybersecurity intelligence

News and Analysis

RayzeBio, Neumora Perk Up the IPO Market, Raising $561M for Clinical Trials

RayzeBio and Neumora Therapeutics have successfully entered public markets, with both firms offering multiple drug candidates in clinical trials. RayzeBio’s IPO, the larger of the two, raised $311 million. The company targets radiation cancer therapies and has a lead program, RYZ101, for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Neumora raised $250 million for its ongoing pivotal testing of a novel major depressive disorder drug.

Source: –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts